Platelet transmission electron microscopy for the assessment of poor biological response to antiplatelet agent: pilot descriptive and prospective study - ELECTROSTROKE
- PMID: 35379612
- PMCID: PMC8981285
- DOI: 10.1136/bmjopen-2021-050060
Platelet transmission electron microscopy for the assessment of poor biological response to antiplatelet agent: pilot descriptive and prospective study - ELECTROSTROKE
Abstract
Introduction: Ischaemic stroke is the leading cause of adult disability. Thus, a strategy based on an efficient antiplatelet therapy has been developed. The monitoring of antiplatelet therapy is now limited to high risk and poor prognosis patients. Indeed, the biological monitoring of the antiplatelet therapy with available platelet function assays do not provide a global integrative approach. Platelet transmission electron microscopy, recently validated for assessing distinct ultrastructural abnormalities is a reliable morphological platelet structural analysis tool which could be used to collect all the ultrastructural platelet characteristics and assess the degree of activation of platelets.
Methods and analysis: Our pilot prospective and descriptive study will include 50 consecutive patients hospitalized for an ischaemic stroke. We expect to identify ultrastructural characteristics that will be correlated with the degree of platelet activation to guide clinicians in decision making regarding the antiplatelet therapy strategy.
Ethics and dissemination: The French Ethics Committee (comité de protection des personnes d'Ile-de-France VII) approved the information notice that will be given to participants and the protocol of this trial (protocol No 21-031).The results of the trial will be disseminated through scientific publications.
Trial registration number: NCT05004233.
Keywords: Stroke; Stroke medicine; Vascular medicine.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures


Similar articles
-
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.Eur J Neurol. 2013 Feb;20(2):344-52. doi: 10.1111/j.1468-1331.2012.03861.x. Epub 2012 Sep 20. Eur J Neurol. 2013. PMID: 22994699 Clinical Trial.
-
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e84-92. doi: 10.1016/j.jstrokecerebrovasdis.2012.07.012. Epub 2012 Sep 13. J Stroke Cerebrovasc Dis. 2013. PMID: 22981273
-
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.Trials. 2010 May 12;11:51. doi: 10.1186/1745-6215-11-51. Trials. 2010. PMID: 20459856 Free PMC article. Clinical Trial.
-
Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis.J Neurol. 2020 Oct;267(10):3021-3037. doi: 10.1007/s00415-020-09932-y. Epub 2020 Jun 9. J Neurol. 2020. PMID: 32518978
-
Antiplatelet effect of aspirin in patients with coronary artery disease.Dan Med J. 2012 Sep;59(9):B4506. Dan Med J. 2012. PMID: 22951204 Review.
References
-
- Kernan WN, Ovbiagele B, Black HR, et al. . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2014;45:2160–236. 10.1161/STR.0000000000000024 - DOI - PubMed
-
- Gachet C. [Molecular mechanisms of platelet activation]. Bull Acad Natl Med 2013;197:361–73. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical